Biobank - Investigating the Gut Microbiota, Genetics, Epigenetics and Metabolites
Observational · No treatment assigned · 1 site · Chinese University of Hong Kong
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Inflammatory Bowel Diseases. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- Patient ≥18 with a diagnosis of Crohn's disease or ulcerative colitis
- Informed Consent obtained
There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 6000 participants are expected to take part.
- Start date: 2014-03.
- Main results expected around 2034-02 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Hong Kong.
Main thing being measured
- Setup a large scale biobank (20 years)
In the researchers’ words
Inflammatory bowel disease (IBD) affects 1 in 500 to 1,000 people in the West. Previously a disease predominantly of the West, there is now a marked increase in the incidence of ulcerative colitis (UC) and Crohn's disease (CD) in Asia, with an estimated prevalence of 1 in 3,000 and 1 in 10,000 respectively\[1\].
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Inflammatory Bowel Diseases |
| Lead sponsor | Chinese University of Hong Kong |
| Enrollment | 6000 (estimated) |
| Start date | 2014-03 |
| Primary completion (est.) | 2034-02 |
| First posted | 2019-02-27 |
| Last updated | 2023-02-08 |
| Official title | Investigating the Intestinal Microbiota, Epigenetic Markers and Body Fluid Metabolites to Identify Biomarkers for Inflammatory Bowel Diseases |
| ClinicalTrials.gov ID | NCT03855657 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: * Patient ≥18 with a diagnosis of Crohn's disease or ulcerative colitis * Informed Consent obtained Exclusion Criteria: * Known current infection with an enteric pathogen * Previously been diagnosed with IBD (Control) * Have a first of second degree relative with IBD (Control)
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Prince of Wales Hospital | Hong Kong | Hong Kong | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.